相似文献
1
Efficacies of four antifungal agents in experimental murine sporotrichosis.
Antimicrob Agents Chemother. 1988 Nov;32(11):1619-23. doi: 10.1128/AAC.32.11.1619.
2
In Vitro and In Vivo Efficacy of Amphotericin B Combined with Posaconazole against Experimental Disseminated Sporotrichosis.
Antimicrob Agents Chemother. 2015 Aug;59(8):5018-21. doi: 10.1128/AAC.00052-15. Epub 2015 May 26.
3
Comparison of two in vitro antifungal sensitivity tests and monitoring during therapy of Sporothrix schenckii sensu stricto in Malaysian cats.
Vet Dermatol. 2017 Feb;28(1):156-e32. doi: 10.1111/vde.12417.
4
[Experimental cutaneous sporotrichosis: in vivo evaluation of itraconazole and terbinafine].
Rev Soc Bras Med Trop. 2009 Nov-Dec;42(6):706-10. doi: 10.1590/s0037-86822009000600018.
5
Refractory sporotrichosis due to Sporothrix brasiliensis in humans appears to be unrelated to in vivo resistance.
Med Mycol. 2017 Jul 1;55(5):507-517. doi: 10.1093/mmy/myw103.
6
Amphotericin B, alone or followed by itraconazole therapy, is effective in the control of experimental disseminated sporotrichosis by Sporothrix brasiliensis.
Med Mycol. 2015 Jan;53(1):34-41. doi: 10.1093/mmy/myu050. Epub 2014 Oct 11.
7
Fungemia caused by an amphotericin B-resistant isolate of Sporothrix schenckii. Successful treatment with itraconazole.
Arch Pathol Lab Med. 1989 Nov;113(11):1279-81.
8
Melanins Protect Sporothrix brasiliensis and Sporothrix schenckii from the Antifungal Effects of Terbinafine.
PLoS One. 2016 Mar 31;11(3):e0152796. doi: 10.1371/journal.pone.0152796. eCollection 2016.
9
Efficacy of posaconazole in murine experimental sporotrichosis.
Antimicrob Agents Chemother. 2012 May;56(5):2273-7. doi: 10.1128/AAC.05376-11. Epub 2012 Feb 13.
10
Efficacy of a poly-aggregated formulation of amphotericin B in treating systemic sporotrichosis caused by Sporothrix brasiliensis.
Med Mycol. 2018 Apr 1;56(3):288-296. doi: 10.1093/mmy/myx040.
引用本文的文献
1
Current Models to Study the -Host Interaction.
Front Fungal Biol. 2022 Feb 25;3:833111. doi: 10.3389/ffunb.2022.833111. eCollection 2022.
2
Systematic repurposing screening in xenograft models identifies approved drugs with novel anti-cancer activity.
PLoS One. 2014 Aug 5;9(8):e101708. doi: 10.1371/journal.pone.0101708. eCollection 2014.
3
Efficacy of posaconazole in murine experimental sporotrichosis.
Antimicrob Agents Chemother. 2012 May;56(5):2273-7. doi: 10.1128/AAC.05376-11. Epub 2012 Feb 13.
4
Antifungal therapy in an athymic murine model of chromoblastomycosis by Fonsecaea pedrosoi.
Antimicrob Agents Chemother. 2011 Aug;55(8):3709-13. doi: 10.1128/AAC.01662-10. Epub 2011 May 16.
5
In vitro antifungal susceptibilities of five species of sporothrix.
Antimicrob Agents Chemother. 2008 Feb;52(2):732-4. doi: 10.1128/AAC.01012-07. Epub 2007 Nov 26.
6
Animal models: an important tool in mycology.
Med Mycol. 2007 Dec;45(8):657-84. doi: 10.1080/13693780701644140.
7
In vitro susceptibilities of isolates of Sporothrix schenckii to itraconazole and terbinafine.
J Clin Microbiol. 2004 Sep;42(9):4319-20. doi: 10.1128/JCM.42.9.4319-4320.2004.
8
Efficacy of antifungal therapy in a nonneutropenic murine model of zygomycosis.
Antimicrob Agents Chemother. 2002 Jun;46(6):1953-9. doi: 10.1128/AAC.46.6.1953-1959.2002.
9
Use of terbinafine in mouse and rat models of Pneumocystis carinii pneumonia.
Antimicrob Agents Chemother. 2002 Feb;46(2):514-6. doi: 10.1128/AAC.46.2.514-516.2002.
10
Experimental chemotherapy with combinations of ergosterol biosynthesis inhibitors in murine models of Chagas' disease.
Antimicrob Agents Chemother. 1993 Jun;37(6):1353-9. doi: 10.1128/AAC.37.6.1353.
本文引用的文献
1
Five unusual cases of sporotrichosis from South Africa showing lesions in muscles, bones, and viscera.
Br J Surg. 1963 May;50:585-91. doi: 10.1002/bjs.18005022406.
2
Treatment of experimental sporotrichosis in mice with griseofulvin and amphotericin B.
Antibiot Chemother (Northfield). 1960 Dec;10:753-7.
3
Treatment of fungal infections in the bones and joints with ketoconazole.
J Infect Dis. 1983 Jun;147(6):1064-9. doi: 10.1093/infdis/147.6.1064.
4
Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study.
Ann Intern Med. 1983 Jan;98(1):13-20. doi: 10.7326/0003-4819-98-1-13.
5
Clinical features of extracutaneous sporotrichosis.
Medicine (Baltimore). 1967 May;46(3):265-79. doi: 10.1097/00005792-196705000-00002.
6
Local heat in the treatment of sporotrichosis.
Mycopathol Mycol Appl. 1966 Oct 4;30(1):47-53. doi: 10.1007/BF02051708.
7
Experimental therapy of cladosporiosis and sporotrichosis with 5-fluorocytosine.
Antimicrob Agents Chemother. 1973 Jan;3(1):95-8. doi: 10.1128/AAC.3.1.95.
8
5-fluorocytosine in the treatment of mycotic infections.
Ann Intern Med. 1972 Jul;77(1):43-51. doi: 10.7326/0003-4819-77-1-43.
9
Bioassay for SF 86-327, a new antifungal agent.
Antimicrob Agents Chemother. 1986 Oct;30(4):628-9. doi: 10.1128/AAC.30.4.628.
10
Antifungal activity of the allylamine derivative terbinafine in vitro.
Antimicrob Agents Chemother. 1987 Sep;31(9):1365-8. doi: 10.1128/AAC.31.9.1365.
Zotero 插件